Podcasts about Roche

Elle s'appelle Elisa Deroche, Raymonde de Laroche ou encore la Baronne de Laroche. Elle est à la fois une et multiple mais à l'aube du XXe siècle, tout son être est tendu vers un seul objectif : la conquête du ciel. C'est ainsi qu'elle va s'imposer comme la première véritable femme-pilote au monde. Un destin hors normes, entre grandes joies et grandes tragédies.Embarquez pour un fascinant voyage dans le temps à l'aube de l'aviation ! Suivez les aventures extraordinaires d'Elisa de Roche, cette femme audacieuse qui a bravé tous les obstacles pour devenir l'une des premières aviatrices au monde. Jeune femme libre et passionnée de mécanique, Elisa Deroche va peu à peu se faire un nom dans le milieu naissant de l'aéronautique. Malgré les réticences de son entourage, elle va résolument prendre les commandes d'un avion et s'élever dans les airs, devenant ainsi une véritable star de l'époque. Les journaux se disputent ses exploits, la surnommant tour à tour 'la baronne de l'air' ou 'le petit oiseau'. Mais son ascension fulgurante est aussi marquée par de terribles épreuves. La mort brutale de sa fille, puis celle de son mentor, vont profondément la bouleverser. Malgré les dangers, elle ne cessera pourtant de repousser les limites, décrochant records sur records. Jusqu'à ce tragique accident qui mettra fin à sa carrière d'aviatrice.Plongez dans l'épopée captivante d'une femme hors du commun, qui a su s'imposer dans un monde d'hommes et écrire une page de l'histoire de l'aviation.

Networking gets a bad reputation. And honestly? It's earned it.For most people, the word conjures images of awkward small talk, business cards nobody keeps, and conversations that feel more like auditions than actual human connection. It feels transactional. It feels fake. And for a lot of women, especially, it feels like a game they were never taught how to play.But what if the problem isn't networking itself — it's the way we've been taught to think about it?On the 2B Bolder Podcast, host Mary Killelea sits down with Monique Kelley — professor, consultant, and author of Redefining Networking: How to Lead with Your Unique Value, an Amazon #1 Bestseller in Business Ethics — to completely reframe what networking is, what it isn't, and why getting it right might be the single most important career move you make.Monique is a two-time PRNEWS Top Women in PR award recipient, a founding member of CHIEF, and has been featured in FOX and Fast Company. She's built a career working with some of the biggest names in biopharma — Pfizer, Roche, Lilly, Johnson & Johnson — not by chasing opportunities, but by building meaningful relationships that opened doors long after the conversation ended. Today she teaches the only Career Readiness course at Boston University's College of Communication, shaping how the next generation of professionals show up, connect, and lead.This conversation covers it all — her career journey from a pre-med detour into communications and healthcare PR, the moment she stepped in to present to a major client when her boss was out and realized that relationships matter just as much as the deck, and the pivots that took her from agency life to in-house roles to fractional consulting and eventually the classroom.Mary and Monique dig into the real stuff:What most people fundamentally get wrong about networking — and why that misunderstanding is costing them real opportunitiesWhat "leading with your value" actually means in practice, not just as a concept but as a daily behaviorA clear, three-step framework for defining your unique value, choosing the right audience, and showing up consistently — on LinkedIn and beyondWhy your network isn't a list of contacts. It's a living system of people who understand what you bring and actively want to advocate for youHow to build a network from scratch when you feel like you have nothing to offer and nowhere to startWhy remote work and meeting overload are making organic connection harder than ever — and what to do about itThe truth about "I don't have time to network" (spoiler: it's a prioritization issue, not a time issue)What Monique is seeing right now across executives, students, and mid-career professionals — and the specific behaviors she notices in women who are actually building momentumWhat she teaches her Career Readiness students at BU that experienced professionals desperately need to hearAnd the one thing she wishes she had understood earlier about building a career that lastsWhether you're in the middle of a career transition, feeling stuck in a role that no longer fits, or just dreading the next industry event — this episode will completely shift how you think about connection, value, and what it actually means to build a career on your own terms.

This week on the Long Island Tea Podcast, Stacy and Sharon catch listeners up on their recent adventures across Suffolk County, from delivering Suffolk 250 Passports to local students and attending the U.S. Open at Shinnecock Hills to teasing several exciting remote podcast recordings coming up in the weeks ahead. They also dive into the stories shaping summer on Long Island, including the growth of beloved community events, waterfront destinations, maritime history, Fire Island's cultural significance, Long Island's thriving food scene, and the people helping make the region such a special place to live, work, and visit.#ShowUsYourLongIslanderThis week's spotlight features Mike McElwee of the Bay Shore Restaurant Committee, who reflects on the remarkable growth of Alive by the Bay as the event enters its ninth summer season. Mike shares how the initiative began in 2017, the impact it has had on the Bay Shore community, and what visitors can look forward to during this year's events on June 30, July 14, July 28, and August 11.Show us YOUR Long Islander by sending us a DM or emailing spillthetea@discoverlongisland.com.#LongIslandRevolutionaryRootsThis week we're taking to the water with the arrival of the Liberty Clipper in Port Jefferson Harbor. The 125-foot traditionally rigged tall ship is now offering sailing excursions through the end of June before participating in America's 250th Anniversary Tall Ships Parade. We also spotlight the return of the historic Selina II to the East End, bringing a century of Long Island maritime history back home.#LongIslandLifeWe're discussing the opening of Faraway Sag Harbor, a newly reimagined waterfront hotel bringing fresh energy to one of Long Island's most beloved villages.We also celebrate the Knicks' championship run and the pride it has inspired throughout Long Island's Puerto Rican and Dominican communities, spotlight Fire Island's fascinating history as an LGBTQ+ destination, and explore the many communities that make the barrier island one of Long Island's true crown jewels.Plus, we highlight National Foodie Day and some of the incredible restaurants that continue to make Long Island a premier culinary destination.Additional topics include the lasting impact of the U.S. Open at Shinnecock Hills and several standout public golf courses that keep Long Island's golf legacy thriving long after championship weekend.#ThisWeekendOnLongIslandFriday, June 26• Bop To The Top (18+) – The Paramount, Huntington• Summer Hours Begin – Adventureland• Beautiful: The Carole King Musical – Argyle Theatre (All Weekend)Saturday, June 27• Joe Avati – Patchogue Theatre for the Performing Arts• East End Farmers Markets – Greenport, Westhampton Beach & Sag Harbor• 4th Annual North Fork Pride Parade – Greenport Village• Bug Light Cruise – East End Seaport Museum• Fauna After Dark – Westhampton BeachSunday, June 28• Farmers Markets – Port Jefferson & SouthamptonFor more events and things happening across Long Island, visit discoverlongisland.com/events.#CelebriTEAThis week we're spotlighting Commack artist Ian James Roche, who has advanced to the quarterfinals of Johnny Depp's People's Artist Competition. Known for his large-scale pastel works, Roche is earning national recognition while representing Long Island's vibrant and growing arts community.Learn how to vote here: https://peoplesartist.org/vote/free/2...Connect with us:Instagram: @longislandteapodcastTikTok: @longislandteapodcastYouTube: Discover Long IslandFacebook: Long Island Tea PodcastX: @liteapodcastEmail: spillthetea@discoverlongisland.comShop: Discover Long Island Shop Hosted on Acast. See acast.com/privacy for more information.

Ecoutez les infos de ce lundi 22 juin à 18h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Check out the video version of this episode on HCPLive!Finerenone's expansion into non-diabetic kidney disease is prompting a broader rethink of how chronic kidney disease is measured, mechanistically understood, and treated across its many causes.On an episode of Don't Miss a Beat recorded at the 10th Annual Heart in Diabetes Meeting, hosts Stephen Greene, MD, meeting co-chair and heart failure specialist at Duke University School of Medicine, and Muthiah Vaduganathan, MD, MPH, codirector of the Center for Cardiometabolic Implementation and cardiologist at Brigham and Women's Hospital, spoke with Katherine Tuttle, MD, professor of medicine at the University of Washington, about the phase 3 FIND-CKD trial and how it informs on the overall role of finerenone (Kerendia) in management of cardiovascular-kidney-metabolic syndrome.FIND-CKD showed finerenone slowed total estimated glomerular filtration rate (eGFR) slope by 0.7 mL/min/1.73 m² per year versus placebo, irrespective of diagnosis. Much of the discussion focused less on the number and more on why it counts as clinically meaningful.Drawing on CKD Prognosis Consortium data from hundreds of thousands of patients, Tuttle explained why eGFR slope reliably predicts kidney failure when a trial runs at least 2 years. CKD progresses rather than striking as a discrete event, so the field has moved toward endpoints measurable without waiting for organ failure or death.On safety, hyperkalemia occurred more often with finerenone than placebo, about 12% versus 3%, though fewer than 1% of patients discontinued. The framing was practical, with background SGLT2 inhibition expected to lower the risk.Mechanism anchors much of the conversation between Tuttle, Greene, and Vaduganathan.Tuttle highlighted how glomerular diseases, like IgA nephropathy, are immunologic disorders needing disease-specific therapy, yet all CKD converges on shared final common pathways of inflammation and fibrosis. Broad agents like finerenone target those pathways, making combination therapy the emerging model, pairing treatment of the inciting disease with control of progression.The group also discussed the field's trend toward precision nephrology. Protocol biopsies from the Kidney Precision Medicine Project showed only about half of patients labeled as diabetic CKD had classic diabetic nephropathy. A parallel to oncology followed, where deep phenotyping replaced uniform regimens, suggesting not every patient will need every drug.Tuttle positioned finerenone alongside renin-angiotensin system inhibitors and SGLT2 inhibitors as an emerging pillar for non-diabetic CKD, with GLP-1 receptor agonists and endothelin antagonists possibly to come. A pooled analysis of FIDELIO-DKD, FIGARO-DKD, and FIND-CKD showed roughly 30% reductions in kidney and cardiovascular outcomes and an 11% drop in all-cause mortality. The closing point held the cardiorenal patient often arrives through either specialty's door, making preservation of organ function and quality of life the shared aim.Relevant disclosures for Tuttle include Alnylam, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GSK, Novo Nordisk, Roche, and Travere Therapeutics. Relevant disclosures for Vaduganathan include Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, Lexicon, and others. Relevant disclosures for Greene include Amgen, AstraZeneca, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, and others.References: Heerspink HJL, Neuen BL, Agarwal R, et al. Finerenone in Persons with Chronic Kidney Disease without Diabetes. N Engl J Med. Published online June 4, 2026. doi:10.1056/NEJMoa2604625 Bayer. Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026. Bayer.com. Published June 2, 2026. Accessed June 21, 2026. https://www.bayer.com/en/us/news-stories/kerendia-in-non-diabetic-chronic-kidney-disease

Ecoutez les infos de ce lundi 22 juin à 06h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce lundi 22 juin à 07h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce lundi 22 juin à 08h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce lundi 22 juin à 12h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce lundi 22 juin à 16h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce lundi 22 juin à 17h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce lundi 22 juin à 09h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce dimanche 21 juin à 12h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce dimanche 21 juin à 09h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce dimanche 21 juin à 17h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce samedi 20 juin à 08h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce samedi 20 juin à 12h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce samedi 20 juin à 16h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce samedi 20 juin à 18h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce vendredi 19 juin à 06h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce vendredi 19 juin à 08h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce vendredi 19 juin à 12h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce vendredi 19 juin à 16h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce vendredi 19 juin à 17h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce vendredi 19 juin à 18h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce vendredi 19 juin à 19h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Ecoutez les infos de ce vendredi 19 juin à 07h avec le flash info de la rédaction d'ACTIV. L'actualité à Saint-Etienne, Saint-Chamond, Roanne, Firminy, Montbrison, Rive-de-Gier, Saint-Just-Saint-Rambert, Le Chambon-Feugerolles, Riorges, Andrézieux-Bouthéon, Roche-la-Molière, Veauche, Unieux, Feurs, Villars, Sorbiers, La Ricamarie, Mably, Le Coteau, La Talaudière...Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

“It’s designed to be simple in a way, even though it’s an incredibly complex device”, Distalmotion CEO Greg Roche explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Roche sits down with BI analyst Matt Henriksson for an in-depth interview on the company, how its Dexter Robotic Surgery System and single-use instrument platform differentiates itself from others in the robotic market and how it can shorten the learning curve that can increase adoption of robots in ambulatory surgical centers.See omnystudio.com/listener for privacy information.

Immigration Minister Erica Stanford issued a scathing takedown of her ministry, saying officials "deliberately withheld" information from both her and the previous Labour government about a failed technology upgrade. Public Service Commissioner Sir Brian Roche will be investigating the process, and spoke to John Campbell.

Executive transitions are more fragile than most people assume. 40% of executive appointments fail within the first 18 months, not because of technical incompetence, but because of people, politics, and culture. And yet organisations continue to spend 90% of their budget on selection, and only 10% on supporting the executive once they are in the role. In this episode, we speak with Navid Nazemian about what actually goes wrong, and what a more deliberate approach to transition looks like.We discuss why the skills that get you hired into the C-suite are rarely the ones that determine whether you succeed, what Marshall Goldsmith’s “what got you here won’t get you there” really means in practice, and why vertical development (expanding how you think, not just what you know) matters more than most executives realise. Navid also walks us through his Double Diamond Framework©, a seven-phase approach to executive transitions spanning twelve to eighteen months. We touch on the pre-onboarding phase, stakeholder mapping, and why phases one and seven (the ones that bookend the entire journey) are almost always the first to get skipped. Our Guest: Navid Nazemian Navid Nazemian is the world’s #1 executive coach, ranked by CEO Today three years running, and the international bestselling author of Mastering Executive Transitions. A former global HR leader at Vodafone, Roche, and BAT, he has coached 350+ executives across five countries — more than half of them CEOs. He’s the creator of the Double Diamond Framework© and lives in Dubai. References: Navid Nazemian LinkedIn profile Listen to the next Episode All Podcast Episodes

Oliver speaks to designer, and Charlie Mackesy's collaborator, Colm Roche.

Welcome to IDEA Collider. In this episode, host Dr. Alex Gray, Chief Medical and Innovation Officer at IDEA Pharma, is joined by colleague Jacqueline Poot, President of Strategic Consulting and Analytics, to discuss the intricacies of pharmaceutical portfolio strategy.  This episode has accompanying slides that can be found on YouTube https://youtu.be/DKdy_MShWBA They tackle the growing view that the pharmaceutical industry doesn't just have a science problem; it has an execution problem. Alex breaks down how human biases, such as confirmation bias and champion bias, can derail clinical development and lead to poor portfolio choices. They emphasize that stopping a failing project early is just as critical to an organization's overall success as advancing a good one.  The episode explores successful decision-making frameworks from top-performing companies, analyzing how AstraZeneca's 5Rs framework reversed late-stage failures and examining structured matrices such as Roche's RAVE, Amgen's RAVE, and Pfizer's DICE. Alex also highlights Eli Lilly's highly successful Chorus unit and their use of AI to drive objective resource allocation. Tune in to hear why relying solely on standard Probability of Technical Success (PTS) models or Risk-Adjusted NPV is flawed, how operational issues drive numerous Phase 3 failures, and the incremental but powerful role machine learning will play in the next generation of drug development.

Tous les matins à 7h42, l'invité qui fait l'actualité. Un acteur incontournable, un expert renseigné... 10 minutes d'interview sans concession avec Apolline de Malherbe et les témoignages des auditeurs de RMC au 3216.

In this episode, Maddy Roche sits down with Sherrill Wayland, Senior Director of Special Initiatives and Partnerships at SAGE, the country's largest and oldest organization dedicated to improving the lives of LGBTQ+ older adults. Sherrill brings over two decades of advocacy experience, a deeply personal connection to the community she serves, and a clear-eyed understanding of what it means to age as an LGBTQ+ adult in a world that was not always built to support you -- particularly when you are doing it without children.In This Episode, You'll Learn:Why LGBTQ+ older adults face a unique set of aging challenges rooted in a lifetime of discrimination, family estrangement, and a legal system that was not designed with their relationships in mind -- and what SAGE is doing at the national level to change thatWhat the Long-Term Care Equality Index is, how it helps LGBTQ+ older adults identify affirming housing and care communities, and what specific questions to ask when evaluating whether a provider is truly equipped to serve your communityHow SAGE Care's cultural competency training is equipping senior centers, assisted living facilities, and area agencies on aging across the country to serve LGBTQ+ older adults with dignity and respectWhat Sherrill's sabbatical to Antarctica with her mother taught her about the freedom that comes with being Childfree by choice, and why building a life on your own terms sometimes means spending it exactly the way you wantEpisode Guest:Sherrill Wayland (she/they) is the Senior Director of Special Initiatives and Partnerships at SAGE, the country's largest and oldest organization dedicated to improving the lives of LGBTQ+ older adults. With a career rooted in advocacy for marginalized communities, Sherrill oversees the National Resource Center on LGBTQ+ Aging, SAGE Care, SAGE Collab, and SAGE U, and has spent over two decades working to ensure LGBTQ+ elders have access to affirming, dignified care and community.Learn more about SAGE on their website: https://www.sageusa.org/And follow along on social media: https://www.instagram.com/sageusa https://www.facebook.com/SAGEUSA Episode Host:Maddy Roche (she/her) is Chief Growth Officer at Childfree Trust®. She understands the challenges of being Childfree as it relates to estate planning and is passionate about educating her community about ways to prepare.About Childfree Insights:Childfree Insights is the trusted education hub for people who are Childfree or permanently Childless. It provides guidance on finances, estate planning, relationships, and life decisions for adults without children. Home of Childfree Wealth® and Childfree Trust®, supporting long-term planning for people living without kids.Connect with Us:Ready to work on building better financial habits? Connect with our financial planning team at childfreewealth.com or learn more about estate planning at childfreetrust.com.Follow Childfree Life by Design on your favorite podcast platform and join the conversation on social media:Instagram: https://www.instagram.com/childfreeinsightsFacebook: https://www.facebook.com/ChildfreeInsights/LinkedIn: https://www.linkedin.com/company/childfreeinsightsYouTube: https://www.youtube.com/@ChildfreeInsightsDisclaimer: This podcast is for educational & entertainment purposes. Please consult your advisor before implementing any ideas heard on this podcast.

Just going to pat myself on the back for the restraint shown in not including Joey in the episode art this week."The Making Of Mina The Hollower" Game Informer DocumentaryDiscussed: Sleepy BB, Sick Steve, Overworld, Summer Game Fest, post-leakage, direct predictions, Final Fantasy VII Revelation, revisiting Rebirth, Roche redemption, Resident Evil Veronica, the return of Claire, Guild Wars 3, Alien Isolation 2, Gen Atlas, Guild Wars 3, Tifa in Street Fighter, Vincent in Guilty Gear, Spyro: A Realm Beyond, Persona 6, Persona 4 Revival, Teddie's new voice, Mina the Hollower Find us everywhere: https://intothecast.onlineBuy some merch, if you'd like: https://shop.intothecast.onlineJoin the Patreon: https://www.patreon.com/intothecast---Follow Stephen Hilger: https://bsky.app/profile/stephenhilger.bsky.socialFollow Brendon Bigley: https://bsky.app/profile/bb.wavelengths.onlineProduced by AJ Fillari: https://bsky.app/profile/ajfillari.bsky.social---Season 8 cover art by Scout Wilkinson: https://scoutwilkinson.myportfolio.com/Theme song by Will LaPorte: https://ghostdown.online/---Timecodes:(00:00) - Intro (00:36) - Sleebby (01:57) - Catching up on all the announcements (02:14) - Overworld.vg and some SGF (06:24) - This episode is post-Nintendo Direct (07:02) - Nintendo Direct predictions (33:10) - Final Fantasy VII Revelation | SGF (47:25) - Resident Evil Veronica | SGF (48:58) - Alien Isolation 2 and Gen Atlas | SGF (49:30) - Guild Wars 3 | SGF (53:42) - Street Fighter 6 Year 4 | SGF (56:00) - Spyro: A Realm Beyond | SGF (57:05) - Persona 6 | SGF (01:03:15) - Persona 4 Revival | SGF (01:09:47) - Break (01:09:48) - Mina the Hollower | An update (01:34:30) - Warpping up ---Thanks to all of our amazing patrons, including our Eternal Gratitude members:Michael CBrian MSuperThisWayNick GStarfallrondoSusan H0nlygh0stsVincent JPatrick KEd ASamantha DNorth HeroSam HSnzznGregory Mark SCmndr BiscuiticemanChristian HRydan BCaleb HArden FEye of the DuckKaleNathan EJ. H. AjoelchronoMellowMatthew BRobin LPSeekingSeakingJimmerszoey!Vinny MMattKerry KBrian MNoah DZach DChristopher TDHugo WToddChris BLukerfuffleStephen YDaniel GEric FTaran WBrendan OChris ZClayton MZach RDylan NFederico VTigerz RevengeLogan HAlan RJohn AMike LmattjanzzDavid MHeavyPixelsKaleb HTyler JCorey ZSusan HBarry TRobert RChris JBrett Allen HDan SJack SGarrett CjimiiboJohn HDirch FJim EJim WTristan LEvan BAwfulHanzomin2Aaron GJean HTodd Nred_wagonNeilPeter BJohn VvErik MRedmage77Joshua JTony LDanny KGibson GKate Duncan BRichard MDaniel NSeth MJamesAndy HDemoEmmaLyn ECorey TCaleb WJake LJesse WMike TCodesMatt BWesleymebezacAlex LSergio LninjadeathdogRory BA42PoundMooseRobert MMichael WAndrewthis_JUSTINRyan O14.3 billion yearsBrendan KMegan BSecretAgentKoalaNoah OArcturusAndrew WhepaheChase ALoveDiesNick QChris MRBKaren HAdam FScott HAlexander SMatt HMurrayDavid PJason KMicah OKamrin HAndrew DKyle SPhilip N  ★ Support this podcast on Patreon ★

In this episode of Lab Rats to Unicorns, John Flavin sits down with Heather Turner, CEO of LB Pharmaceuticals, a late-stage clinical biotechnology company developing differentiated therapies for patients with serious psychiatric and neurological disorders. Heather's path into biotech was anything but traditional. Trained as an attorney, she began her career advising startup companies at Cooley before spending more than two decades helping build and scale life sciences companies through financings, strategic partnerships, and major transactions. Along the way, she developed a unique perspective on leadership, risk management, and company building—eventually transitioning from legal leadership roles into the CEO seat. The conversation explores Heather's journey from lawyer to biotech executive, the lessons learned leading Carmot Therapeutics through a $3.1 billion acquisition by Roche, and the challenges of raising capital in one of biotech's most difficult financing environments. She also shares how LB Pharmaceuticals successfully completed a public offering to advance its lead program, LB-102, a potential new treatment for schizophrenia, bipolar depression, and major depressive disorder. At its core, this episode is about leadership in uncertainty—how great companies are built through preparation, resilience, humility, and a relentless focus on patients. Heather offers valuable insights on scaling organizations, building high-performing teams, navigating risk, and creating opportunities for the next generation of biotech leaders.

On this episode: we are joined by the incomparable Austin Lee Matthews! You've heard Austin as Roche in the Final Fantasy VII Remake series and as Ash Carbide in the Legend of Heroes series, and likely in many other places too! Check out what else they've worked on here and here, and their social media!

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries is one of constant evolution, characterized by scientific advancements, strategic mergers, and regulatory maneuvers that shape the future of healthcare. In a significant scientific breakthrough, Merck & Co. and Gilead Sciences have made strides in HIV treatment with the development of a weekly pill. This innovative regimen combines Merck's islatravir with Gilead's lenacapavir, showing promise in two phase 3 trials. If approved, this long-acting oral therapy could revolutionize HIV care by offering a more convenient dosing schedule, potentially improving patient adherence and outcomes substantially. This novel regimen signifies progress towards simplifying HIV treatments with once-weekly dosing. Meanwhile, in the oncology sector, Gilead's Trodelvy faced challenges when combined with Merck's Keytruda as a first-line treatment for PD-L1-high non-small cell lung cancer. The phase 3 EVOKE-03 trial was terminated, shifting attention to competitors like AstraZeneca and Daiichi Sankyo, who continue to advance their own therapies in this area. In a strategic move to bolster its position in lung cancer treatment, GlaxoSmithKline (GSK) is acquiring Nuvalent for $10.6 billion, aiming to secure near-approval cancer therapies capable of challenging market leaders like Roche and Pfizer. This acquisition underscores the focus on targeted cancer therapies that increase treatment efficacy by honing in on specific genetic markers. Nuvalent's innovative pipeline of small molecule inhibitors targets drug resistance and mutations in cancer treatment—a strategic addition to GSK's portfolio aimed at enhancing its position amidst rapid advancements and intense competition in oncology. In diabetes and obesity management, Eli Lilly is advancing with its new oral GLP-1 receptor agonist, Foundayo (orforglipron), which has shown competitive efficacy over oral semaglutide. Analysts see Lilly's progress as strengthening its leadership in the growing obesity drug market. Similarly, AstraZeneca is making progress with its own GLP-1 candidate, elecoglipron, as phase 2 data sets the stage for pivotal studies. Promising clinical trial data from Eli Lilly's retatrutide for obesity-related conditions and AstraZeneca's elecoglipron suggest a strengthening pipeline for GLP-1 receptor agonists known for their dual effects on weight management and glycemic control. On the diagnostics front, Roche reaffirms its €600 million investment in Germany amid industry retrenchments by companies like Eli Lilly and Boehringer Ingelheim. However, Roche remains cautious about future risks due to shifting economic conditions. The financial dynamics within biotech are also noteworthy. Parabilis Medicines is planning a potentially record-setting IPO following Kailera Therapeutics' successful public offering earlier this year. These trends indicate strong investor confidence and an influx of funding towards innovative cancer therapies. Meanwhile, CeQur's $100 million Series E funding round aims at accelerating insulin patch delivery systems' commercial growth—highlighting ongoing innovation in diabetes management solutions. Regulatory updates reveal AstraZeneca facing reprimands from the UK marketing watchdog due to repeated breaches related to LinkedIn activities—an ongoing challenge in pharmaceutical marketing compliance. The integration of digital health solutions continues apace as ixlayer partners with Vertex Pharmaceuticals to launch a digital acute pain management platform. This initiative aims at improving patient care by reducing reliance on opioid-based treatments. These developments paint a picture of an industry where scientific innovations, regulatory hurdles, and technological advancements intersect to shape future therapeutic landscapes. Precision oncology is another area witnessing substantial growth. The landscape also sees notable activity in rare disease therapeutics. Johnson & Johnson's Talvey has gained acceptance in Scotland for treating relapsed multiple myeloma using bispecific antibody technology—a trend toward leveraging immune system targeting technologies to enhance cancer treatment efficacy. Moreover, Zai Lab's Tivdak received approval from China's NMPA for cervical cancer treatment based on Phase 3 data, highlighting the rise of antibody-drug conjugates (ADCs) as potent oncology therapies due to their targeted delivery mechanisms. On the research collaboration front, AlzeCure Pharma's partnership with Eli Lilly focuses on Alzheimer's disease research through Alzstatin ACD680—a small molecule targeting neurodegenerative pathways—a testament to the collaborative efforts needed to tackle complex diseases like Alzheimer's. However, challenges persist as Bial discontinued its GCase activator program after failing Phase 2b trials for Parkinson's patients with GBA1 variants—a stark reminder of the high-risk nature inherent in drug development despite initial promise. These myriad developments underscore a vibrant period within pharmaceutical and biotech sectors where scientific advancements rapidly translate into actionable therapies promising substantial improvements in patient care by addressing unmet medical needs globally.Support the show

On this episode: we are joined by the incomparable Austin Lee Matthews! You’ve heard Austin as Roche in the Final Fantasy VII Remake series and as Ash Carbide in the Legend of Heroes series, and likely in many other places too! Check out what else they’ve worked on here and here, and their social media!

Everything came up roses for Eli Lilly at the American Diabetes Association, as the pharma boasted positive results for its new pill Foundayo and next-gen asset retatrutide—not just for weight loss but also for other indications.Obesity rival Novo Nordisk, meanwhile, held a dinner, during which executives may have convinced analysts that the company is turning a corner after a rough couple of years.Also check out ADA updates from Roche and partner Zealand Pharma, Boehringer Ingleheim, Pfizer (touting results from its Metsera buy), AstraZeneca, Kailera Therapeutics and more.Outside of ADA, the biggest news of the past week came on Tuesday with GSK striking the biggest traditional pharma/biotech M&A of the year so far with its $10.6 billion acquisition of oncology focused Nuvalent Bio. And on Monday, J&J notched a smaller deal, buying out Firefly Bio for $1B. These deals add to continued uptick in M&A seen in biopharma this year, with much of that momentum being driven by Eli Lilly and its GLP-1 cash.At an FDA listening meeting last week on the Commissioner's National Priority Voucher program, the agency heard multiple calls to pause it. Confusion also still persists around all of the new rare disease pathways, including the new plausible mechanism framework.

¿Qué posibilidades se abren con el nuevo Espacio Europeo de Datos de Salud? ¿Se atisba la promesa de otros espacios similares? ¿Hasta dónde llegan los usos secundarios de los datos de salud? ¿Qué hacemos con los “wearables”? ¿Dónde terminan las garantías individuales y empieza el beneficio colectivo en el ámbito de la investigación?Mikel Recuero es Doctor en Derecho por la Universidad del País Vasco. Es investigador postdoctoral en la Red de Derecho y Genoma Humano, donde ejerce como experto en asuntos legales, éticos y regulatorios (ELSI) para distintos proyectos nacionales y europeos. Su campo de estudio se centra en las intersecciones entre derecho, ética, ciencia y tecnología. Actividad que compatibiliza con el ejercicio de funciones de consultoría en materia de protección de datos y data governance y con la docencia en varias universidades españolas. Es también miembro del Órgano de Gobierno del Código de Conducta de Protección de Datos de FARMAINDUSTRIA. También es autor de una veintena de publicaciones en revistas científicas y académicas especializadas, ha recibido el Premio de Investigación en Protección de Datos por la Autoridad Vasca de Protección de Datos (AVPD/DBEA) en el año 2024 y el Accésit del Premio de Investigación en Protección de Datos Personales Emilio Aced por la Agencia Española de Protección de Datos (AEPD) en el año 2019.Referencias:* Mikel Recuero en LinkedIn* AA.VV. El Espacio Europeo de Datos de Salud y su implementación en España. Fundación Roche, 2026.* Comité de Bioética de España. Informe sobre aspectos del uso secundario de los datos y el Espacio Europeo de Datos de Salud. 2023.* European Commission. Frequently Asked Questions on the European Health Data Space. Last updated 26th March 2026. Disponible en:* Recuero, Mikel. «El uso secundario de datos de salud electrónicos: el futuro Reglamento del Espacio Europeo de Datos de Salud y su interacción con la protección de datos personales». InDret 2 (2024): 525-51. DOI: 10.31009/InDret.2024.i2.13* Reglamento (UE) 2025/327 del Parlamento Europeo y del Consejo, de 11 de febrero de 2025, relativo al Espacio Europeo de Datos de Salud, y por el que se modifican la Directiva 2011/24/UE y el Reglamento (UE) 2024/2847. «DOUE» núm. 327, de 5 de marzo de 2025, páginas 1 a 96 (96 págs.)* Patricia Muleiro: la gestión de los datos de salud en escenarios complejos (Masters of Privacy, marzo de 2023). This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mastersofprivacy.com/subscribe

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most significant advancements in scientific research, clinical trials, and regulatory landscapes within the industry. These developments are shaping the future of patient care and drug development significantly. Starting with Legend Biotech's LB2501, which achieved an impressive 100% response rate in a Phase 1 study for non-Hodgkin lymphoma using in vivo CAR T-cell therapy. This breakthrough highlights the transformative potential of CAR T-cell therapies in oncology, especially for B-cell lymphomas. Such success opens the door for accelerated regulatory pathways, offering hope to patients with limited treatment options. In another key development, JJP Biologics shared positive interim data from its Phase 1b trial of nebaprubart targeting CD89 in linear IgA disease. This monoclonal antibody is promising in treating autoimmune conditions by targeting specific disease mechanisms. Meanwhile, GSK's Velzatinib (IDRX-42) achieved a 61% response rate in Phase 1/1b trials for gastrointestinal stromal tumors, showing efficacy against cases resistant to treatments like imatinib. Johnson & Johnson's Nipocalimab met its primary endpoint in a Phase 2 study for systemic lupus erythematosus, underscoring the potential of FcRn blockade in managing autoimmune diseases. Zenas Biopharma's Phase 3 data for Obexelimab targeting CD19/FcγRIIB in IgG4-related disease further emphasizes the role of targeted therapies in managing complex autoimmune disorders. On the regulatory front, Foundation Medicine's FoundationOne Blood Test received FDA approval as a companion diagnostic for Pfizer's Talzenna (talazoparib) to treat prostate cancer with homologous recombination repair gene mutations. This approval underscores the growing importance of precision medicine and companion diagnostics in tailoring cancer treatments based on genetic profiles. Additionally, Lupin and Natco Pharma secured FDA approval for their generic version of Eribulin Mesylate Injection, essential for reducing healthcare costs and improving patient access to vital therapies. Eli Lilly's collaboration with Ascidian Therapeutics focuses on RNA exon editing for kidney diseases, potentially revolutionizing treatment approaches by correcting genetic errors at the RNA level. This partnership reflects a burgeoning interest in RNA-based therapies and their capacity to address unmet medical needs. Regeneron expanded its pact with CytomX Therapeutics to develop conditionally active bispecific antibodies, emphasizing innovation in oncology drug discovery. Such collaborations combine expertise across companies to expedite cutting-edge therapies' development. In terms of funding, NewLimit's successful $435 million Series C round aims to advance epigenetic reprogramming medicine towards human trials. This initiative highlights the burgeoning field of aging biology and its implications for extending healthy human lifespan through innovative therapeutic approaches. Similarly, Immu Biosciences raised $53 million to enhance its immunology platform using AI/ML technologies, underscoring AI and machine learning's critical role in accelerating drug development processes. Turning our gaze towards China's expanding influence on the global biotech stage, Akeso's presentation at ASCO 2026 marked a significant milestone as it became the first-ever Chinese dataset featured in a plenary session. This achievement underscores China's growing prominence in biotechnology and highlights its commitment to advancing innovative medical solutions globally. Simultaneously, Gilead's strategic partnership with Cencora aims to enhance access to CAR-T therapies like Yescarta and Tecartus by expanding their network of treatment centers. CAR-T therapies represent a paradigm shift in cancer treatment by offering personalized options for certain types of cancer. Despite challenges such as Roche's setbacks with its oral SERD drug giredestrant in breast cancer trials, innovation continues unabated. Zevra Therapeutics' launch of Miplyffa for Niemann-Pick disease type C exemplifies efforts to transform rare disease markets by improving patient outcomes through increased access and tailored treatment strategies. Finally, Eli Lilly's acquisition spree reflects broader trends where pharmaceutical companies increasingly integrate Chinese innovations into their development pipelines. This period marks a transformative phase characterized by collaboration between global pharma giants and Chinese biotechs, signaling an era where innovation is globalized and aimed at addressing critical healthcare challenges worldwide. These advancements reflect a dynamic period of innovation within the pharmaceutical and biotech industries. The focus on personalized medicine, targeted therapies, and groundbreaking technologies like RNA editing indicates a shift towards more precise treatment modalities. As these discoveries transition from research phases to clinical applications, they hold the potential to transform patient care significantly. Strategic partnerships and substantial funding initiatives illustrate a robust ecosystem supporting these innovations' rapid advancement. As regulatory bodies continue approving novel therapeutics and diagnostics, the emphasis on personalized healthcare will likely drive future developments, ultimately leading to improved patient outcomes worldwide. As we continue navigating these developments, it's clear that the pharmaceutical and biotech sectors are on the cusp of transformative breakthroughs that promise to redefine healthcare delivery across multiple domains. Thank you for tuning into Pharma Daily; stay informed and stay ahead.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of groundbreaking advancements and strategic maneuvers reshaping the landscape of drug development and patient care. In recent news, Moderna and Merck & Co. have reported substantial progress in cancer treatment with their Phase 2b trial results involving Intismeran Autogene combined with Keytruda. This combination therapy, leveraging the innovative mRNA vaccine technology alongside Keytruda, has shown a remarkable 49% reduction in recurrence risk for high-risk melanoma patients. This synergy not only enhances therapeutic options in melanoma but also underscores the transformative potential of mRNA vaccines beyond infectious diseases, suggesting a new frontier for oncology treatments. Bristol Myers Squibb has also made significant strides with its Phase 3 trial results for Izalontamab Brengitecan, an antibody-drug conjugate. This therapy has demonstrated a 40% reduction in death risk among patients with triple-negative breast cancer—an aggressive subtype with historically limited treatment options. The success of this bispecific antibody targeting Trop2 highlights the advancing trend towards precision medicine, where therapies are increasingly tailored to specific genetic and molecular profiles, promising improved patient outcomes. Turning to business developments, Rallybio's merger with Avenzo Therapeutics through a reverse merger transaction marks a notable consolidation trend within the industry. Supported by a $215 million private placement, this merger aims to accelerate drug discovery and development in oncology, emphasizing the importance of strategic collaborations in enhancing therapeutic pipelines. Similarly, MindMaze Therapeutics is streamlining operations post-merger by refocusing on core competencies aligned with broader industry trends towards specialization. Regulatory updates have been equally dynamic. Shionogi's Xocova (Ensitrelvir) has received FDA approval for post-exposure prophylaxis against COVID-19 following successful Phase 3 trials. As a small-molecule protease inhibitor, Xocova enriches the therapeutic arsenal against COVID-19 and reflects ongoing efforts to manage infectious diseases even as the pandemic wanes. Strategic partnerships are further shaping the industry landscape. The collaboration between ASCO and Ryght AI aims to enhance breast cancer trial site selection using artificial intelligence. This initiative signifies a growing trend towards integrating AI and machine learning technologies in clinical trial optimization to streamline processes and improve efficiency—an essential endeavor as trials become more complex and data-driven. Additionally, Sanofi's integration of AI via field agents to enhance efficiencies across business facets highlights how AI adoption is accelerating and promises to reshape drug development processes and patient care strategies significantly. Meanwhile, challenges persist. The FDA's rejection of Cingulate's CTX-1301 due to manufacturing concerns underscores the rigorous regulatory environment that companies navigate. Similarly, Roche's Persevera trial missing its primary endpoint in breast cancer treatment highlights the inherent risks involved in drug development. In scientific advancements, Gilead Sciences has made progress with Livdelzi in treating primary biliary cholangitis (PBC), a rare liver disease. The Phase 3 trial success points to ongoing innovation in rare disease treatments—a critical area for enhancing patient outcomes. On another front, Contraline is advancing its male birth control candidate after securing $92.5 million in funding. This first-in-class topical contraceptive fills a significant gap in male contraceptive options, demonstrating an increasing focus on diversifying reproductive health solutions. In strategic shifts within the industry, Merck is reducing its workforce as part of a broader $3 billion cost-cutting strategy aimed at optimizing operations while investing in innovation and technology. At ASCO 2026, Celcuity shared ambitions to revolutionize breast cancer treatment paradigms through innovative pathway targeting, while GSK introduced a new approach for rare gut cancers—conditions that have seen little advancement over decades. Such initiatives highlight critical roles innovative research plays in oncology. In summary, these developments reflect a vibrant period for the pharmaceutical and biotech sectors characterized by scientific innovation, strategic mergers, regulatory milestones, and ongoing clinical trials that collectively promise to enhance patient care. Emphasis on personalized medicine, expansion of mRNA technology into oncology, and AI-driven efficiencies are poised to redefine approaches across therapeutic domains while navigating stringent regulatory standards and market dynamics that require strategic agility and robust R&D pipelines. Thank you for tuning into Pharma Daily—your source for insightful updates from the world of pharmaceuticals and biotechnology. Stay connected for more groundbreaking news and analysis shaping the future of healthcare.Support the show

Morgan Rogers to Arsenal, Jurrien Timber's Final Chances & PSG Face-Offs - Ft Art de RocheMorgan Rogers to Arsenal? Jurrien Timber races against time for the Champions League Final, while PSG face-offs and tactical battles take centre stage — with Art de Roche joining the show.In today's episode of The Gooner Talk, Arsenal reporter Tom Canton is joined by Art de Roche to break down the latest Arsenal talking points ahead of the biggest game of the season.We discuss the growing links surrounding Morgan Rogers and whether the Aston Villa star could realistically fit Mikel Arteta's plans. Plus, the latest on Jurrien Timber's fitness and whether he still has a chance of making the Champions League Final squad.We also dive into Arsenal vs PSG match-ups, key tactical battles, and where the final could be won or lost.

Chad Tracy replay // Dan Roche outdoes himself with question for Drake Maye //

L'ascension de la Roche de Solutré est une sorte de "pèlerinage" que François Mitterrand accomplissait chaque année entre 1946 et 1995 en gravissant cette roche située près de Mâcon, en Bourgogne. André Dussollier nous dévoile le secret derrière cette étrange tradition de l'ancien président de la République. Tous les jours, retrouvez le meilleur de Laurent Gerra en podcast sur RTL.fr, l'application et toutes vos plateformes. Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

On September 13, 1991, 36-year-old Tom Roche dropped his longtime girlfriend off at work in Burbank, California. He told her he was heading home to work on his motorcycle, and the two made plans to meet for lunch later that day. But Tom never showed up.Editor: Shannon KeirceResearch/Writing: Haley GraySUBMIT A CASE HERE: Cases@DetectivePerspectivePod.com SOCIALInstagram: https://www.instagram.com/detperspective/Twitter: https://twitter.com/detperspectiveFIND DERRICK HERETwitter: https://twitter.com/DerrickLInstagram: https://www.instagram.com/DerrickLevasseurFacebook: https://www.facebook.com/DerrickVLevasseurCRIME WEEKLY AND COFFEECriminal Coffee Company: https://www.CriminalCoffeeCo.comCrime Weekly:  https://crimeweeklypodcast.com/shopADS:1. https://www.Rula.com/Detective - Get started on your mental health journey today!2. https://www.TryFUM.com - Use code DETECTIVE to get a FREE Gift with your Journey Pack!3. Pocket Hose - Text DETECTIVE to 64000 to get a FREE 360 Degree Rotating Pocket Pivot AND a Thumb Drive Nozzle with the purchase of ANY Pocket Hose Ballistic Hose!

(00:00) Roche's walking club is sh*t-stirring right now(19:55.478) TOM CARON is the host/announcer of the Boston Red Sox broadcast on NESN and joins Toucher & Hardy for his weekly segment to talk about all things Red Sox.(35:44.431) Would you rather play a foursome with Fred, Hardy and Wallach OR Felger, Mazz and Big Jim?Please note: Timecodes may shift by a few minutes due to inserted ads. Because of copyright restrictions, portions—or entire segments—may not be included in the podcast.CONNECT WITH TOUCHER & HARDY: linktr.ee/ToucherandHardyFor the latest updates, visit the show page on 985thesportshub.com. Follow 98.5 The Sports Hub on Twitter, Facebook and Instagram. Watch the show every morning on YouTube, and subscribe to stay up-to-date with all the best moments from Boston's home for sports!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

(00:00) Sit back and relax, because it's time for shootin' the breeze with Freddy T!(19:40.247) Fred Toucher on WILD Red Sox-Mike Trout Trade rumor: "I'd Love It"(33:17.963) Roche, Wallach and callers weigh in.Please note: Timecodes may shift by a few minutes due to inserted ads. Because of copyright restrictions, portions—or entire segments—may not be included in the podcast.CONNECT WITH TOUCHER & HARDY: linktr.ee/ToucherandHardyFor the latest updates, visit the show page on 985thesportshub.com. Follow 98.5 The Sports Hub on Twitter, Facebook and Instagram. Watch the show every morning on YouTube, and subscribe to stay up-to-date with all the best moments from Boston's home for sports!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.